Application of M-BSA-PSiNPs nano composite material in preparation of antitumor drugs
By loading the TLR4 agonist M-BSA on porous silicon nanoparticles (PSiNPs), the problem that existing anti-tumor drugs are not effective enough in the treatment of non-small cell lung cancer cells is solved, and the problem of the lack of significant effect of existing anti-tumor drugs in the treatment of non-small cell lung cancer cells is achieved. It significantly mediated the therapeutic effect and tumor suppression of macrophages, improving the treatment efficiency and safety.
Patent Information
- Application Number
- CN202410802991.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-20
- Publication Date
- 2024-11-08
AI Technical Summary
Existing anti-tumor drugs are not effective enough in the treatment of non-small cell lung cancer cells, especially in activate macrophages to secrete proinflammatory cytokines, resulting in insufficient therapeutic effect.
M-BSA@PSiNPs nanocomposites were prepared by loading the TLR4 agonist M-BSA onto porous silicon nanoparticles (PSiNPs), which were loaded onto PSiNPs using hydrophobic interactions, and prepared by sonication and centrifugal washing techniques. Combining the nano-size of porous silicon and the modified surface enhances its enrichment and release effect at the tumor site.
Significantly enhanced the therapeutic effect of macrophage-mediated in vitro anti-non-small cell lung cancer cells, and M1 reprogramming of TAMs induced by M-BSA@PSiNPs significantly inhibited tumor growth, improved treatment efficiency, and under normal or weak acidic conditions It can efficiently release M-BSA and reduce immune side effects.
Smart Images

Figure CN118903388A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of nanocomposite materials, and in particular relates to application of M-BSA@PSiNPs nanocomposite materials in preparing anti-tumor drugs. Background Art
[0002] Porous silicon was accidentally discovered at Bell Labs in 1956. However, the unexpected appearance of porous silicon did not immediately arouse people's interest. It was not until 1989 that Canham discovered that porous silicon had a quantum confinement effect of visible photoluminescence, and people began to conduct in-depth research on it. Nowadays, people have discovered that porous silicon has many excellent properties such as large specific surface area, chemically modifiable surface, and good biocompatibility (degradable into non-toxic orthosilicic acid), and has applied it to many biomedical applications such as drug delivery, bioimaging, biosensing, and immunotherapy, bringing new solutions to the problems and challenges in the medical field. Here, we mainly introduce the relevant research results of porous silicon in the field of immunotherapy.
[0003] Xia et al., based on their discovery that after intravenous injection of PSiNPs, these particles were preferentially phagocytosed by dendritic cells, used PSiNPs loaded with the model antigen OVA for dendritic cell immunostimulation. The results showed that PSiNPs loaded with antigens can effectively promote the maturation of dendritic cells and the successful presentation of antigens, induce T cell proliferation and IL-2 secretion, and also show good anti-tumor effects in vivo. LPS or MPL loaded with PSiNPs can also induce dendritic cell maturation and significantly inhibit tumor growth. Compared with loading a single antigen or immunostimulatory adjuvant, a bionic vaccine with cancer cell membrane as a source of multiple antigens has unique advantages. For example, Li et al. developed a bionic vaccine CCM@PSiNPs@Au with PSiNPs@Au as the core, loaded with 4T1 cell membrane, which can achieve photothermal and weak immunostimulation. This vaccine not only avoids the side effects of strong immunostimulatory adjuvants, but also realizes the synergistic treatment of photothermal therapy and immunotherapy, and has good immunostimulatory and anti-tumor effects. This is also due to the presence of porous silicon as a core carrier.
[0004] In addition to being a carrier, porous silicon can also be used directly or after modification as a nanoadjuvant to stimulate immune responses. In their study of PSiNPs, Xia et al. found that dendritic cells treated with PSiNPs showed a significant increase in IFN-β production and secreted high levels of IFN-I-regulated chemokines, RANTES. This process is achieved by activating TRIF and MAVS-dependent signaling pathways. Meraz et al. also found that PSiNPs can promote the secretion of IL-1β by activating inflammasomes. In addition, Shahbazi et al. evaluated the effects of PSiNPs with different surface treatments on human monocyte-derived dendritic cells (MDDCs) and lymphocytes. The results showed that PSiNPs after thermal oxidation and thermal alkylation were able to induce higher immune activation rates by enhancing the expression of co-stimulatory markers (CD80, CD83, CD86, and HLA-DR) on the surface of MDDCs, inducing T cell proliferation, and the secretion of cytokines (IL-1β, IL-4, IL-6, IL-10, IL-12, IFN-γ, and TNF-α), while PSiNPs after other surface treatments did not induce any immune response. Under multiple modifications, some particles that originally had no immunostimulatory effect can also show a certain immune activation effect. In short, all nanoparticles with more nitrogen or oxygen in the outermost skeleton layer have lower immunostimulatory effects than nanoparticles with a higher CH structure on the surface.
[0005] In summary, porous silicon has great potential as a carrier or immunostimulant in the field of immunotherapy. By loading porous silicon, it is expected to provide new solutions to overcome the problems and challenges in immunotherapy. Summary of the invention
[0006] The first object of the present invention is to provide a method for preparing a M-BSA@PSiNPs nanocomposite material, wherein the TLR4 agonist M-BSA is loaded onto PSiNPs to prepare the M-BSA@PSiNPs nanocomposite material.
[0007] The second purpose of the present invention is to propose the use of M-BSA@PSiNPs nanocomposite materials in the preparation of anti-tumor drugs. Compared with M-BSA or PSiNPs alone, M-BSA@PSiNPs can more efficiently activate macrophages to secrete more proinflammatory cytokines, significantly enhancing the macrophage-mediated in vitro anti-non-small cell lung cancer cell therapeutic effect.
[0008] In order to solve the above problems, the technical solution adopted by the present invention is as follows:
[0009] Application of M-BSA@PSiNPs nanocomposites in the preparation of anti-tumor drugs.
[0010] Furthermore, the anti-tumor drug is a drug that inhibits the growth of tumor cells.
[0011] Furthermore, the tumor cells are non-small cell lung cancer cells.
[0012] Furthermore, the preparation method of the M-BSA@PSiNPs nanocomposite material is as follows: firstly dissolve BSA in PBS to obtain a BSA solution, add an aqueous solution of manganese chloride, stir, dialyze, and freeze-dry to obtain M-BSA; and load M-BSA onto PSiNPs to obtain an M-BSA@PSiNPs nanocomposite material.
[0013] Furthermore, the pH range of PBS is 7.2-7.4; the mass volume ratio of BSA to PBS is 29 mg-31 mg:10 mL.
[0014] Furthermore, the concentration of the manganese chloride aqueous solution is 18.5-19.0 μg / mL.
[0015] Furthermore, the method of loading M-BSA onto PSiNPs is as follows: PSiNPs are dispersed in deionized water by centrifugation, an M-BSA aqueous solution is added, the solution is allowed to stand after ultrasonic treatment, and centrifugally washed with deionized water to obtain a M-BSA@PSiNPs nanocomposite material.
[0016] Furthermore, the concentration of the M-BSA aqueous solution is 0.9-1.1 mg / mL; the mass ratio of PSiNPs to the M-BSA aqueous solution is 2:1.
[0017] Furthermore, the preparation method of the M-BSA@PSiNPs nanocomposite material comprises the following steps:
[0018] (1) Weigh 30 mg of BSA and dissolve it in 10 mL of PBS at a pH of 7.2-7.4 to obtain a BSA solution; add an aqueous solution of manganese chloride at a concentration of 18.9 μg / mL dropwise to the BSA solution, stir, dialyze for 24 h using a dialysis bag with a MWCO of 8-14 kDa, and freeze-dry to obtain M-BSA;
[0019] (2) PSiNPs were dispersed in deionized water by centrifugation, and 500 μL of 1 mg / mL M-BSA aqueous solution was added at a ratio of 2:1. The mixture was ultrasonically treated for 30 min and allowed to stand overnight. The next day, the mixture was washed twice by centrifugation at 13,000 rpm with deionized water to obtain M-BSA@PSiNPs.
[0020] Furthermore, the M-BSA@PSiNPs nanocomposite material is prepared by the method described above.
[0021] Compared with the prior art, the advantages of the present invention are as follows:
[0022] 1) The present invention utilizes hydrophobic interaction to successfully load the TLR4 agonist M-BSA onto PSiNPs to prepare the M-BSA@PSiNPs nanocomposite material. The preparation method is simple and the required conditions are relatively mild.
[0023] 2) The present invention uses porous silicon as a carrier. With its own nanosize, it is beneficial to enrich at the tumor site through the enhanced permeability and retention (EPR) effect. In addition, due to the modifiable active surface, PSiNPs can be used as a carrier of various vaccines or adjuvants in the field of immunotherapy to improve their targeting and reduce immune side effects. In addition, PSiNPs nanocarriers significantly increase the endocytosis of M-BSA by macrophages and enhance the M-BSA regulation of macrophage M1 polarization and anti-tumor effects.
[0024] 3) The combined treatment between the M-BSA@PSiNPs nanocomposite prepared by the present invention and macrophages has a synergistic effect on killing non-small cell lung cancer cells in vitro, especially under conditions of higher concentration and longer incubation time, the effect is particularly significant.
[0025] 4) Compared with M-BSA or PSiNPs alone, M-BSA@PSiNPs can more efficiently activate macrophages to secrete more proinflammatory cytokines, which can significantly enhance the macrophage-mediated therapeutic effect against non-small cell lung cancer cells in vitro; and the M1 reprogramming of TAMs induced by M-BSA@PSiNPs in non-small cell lung cancer tumors can significantly inhibit their growth, with a much higher efficiency than PBS, PSiNPs or M-BSA.
[0026] 5) The M-BSA of the present invention can not only be loaded onto PSiNPs via hydrophobic interactions to form M-BSA@PSiNPs nanocomposites, but can also be efficiently released from the PSiNPs carrier under normal or weakly acidic physiological conditions. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 The hydrodynamic size and zeta potential diagrams of M-BSA, PSiNPs and M-BSA@PSiNPs nanocomposites.
[0028] Figure 2 Infrared spectra of M-BSA, PSiNPs and M-BSA@PSiNPs nanocomposites.
[0029] Figure 3UV-visible absorption spectra of M-BSA, PSiNPs and M-BSA@PSiNPs nanocomposites.
[0030] Figure 4 Full XPS spectra of M-BSA, PSiNPs and M-BSA@PSiNPs nanocomposites and detailed spectra of N1s.
[0031] Figure 5 TEM images and energy spectra of PSiNPs and M-BSA@PSiNPs nanocomposites.
[0032] Figure 6 It is a standard curve diagram between the absorbance of M-BSA at 278 nm and its concentration.
[0033] Figure 7 The dynamic release curve of M-BSA in M-BSA@PSiNPs nanocomposites at pH = 5.4 or 7.4.
[0034] Figure 8 The real-time frequency change diagram of the binding and dissociation of M-BSA and PSiNPs when the chip oscillates at 15 or 35 Hz.
[0035] Fig. 9 The concentration is 0-1.2×10 5 Bioluminescence intensity of Luc-LLC cells at 100 cells / well.
[0036] Fig.10 After treatment with M-BSA@PSiNPs at concentrations ranging from 0 to 1 mg / mL for 24 or 48 h, the 3 In the case of RAW 264.7 cells at 8×10 / mL, Luc-LLC cells were 3 Density proliferation plots of cells / mL (n=4); error bars are based on standard error of the mean (***P<0.001, **P<0.01 by analysis of variance with Tukey's post-test).
[0037] Fig.11 After treatment with 200 μg / mL (or 500 μg / mL) of PSiNPs, 27 μg / mL (67 μg / mL) of M-BSA, or 200 μg / mL or 500 μg / mL of M-BSA@PSiNPs for 24 or 48 h, the cells were cultured in the absence or presence of 1×10 3 In the case of RAW 264.7 cells at 8×10 / mL, Luc-LLC cells were 3Density proliferation plots of cells / mL (n=4); error bars are based on standard error of the mean (***P<0.001, **P<0.01 or *P<0.05 by analysis of variance with Tukey's post-test).
[0038] Fig.12 Figure 2 is a graph of the tumor volume of all mice from the PBS, PSiNPs, M-BSA, and M-BSA@PSiNPs groups within 23 days (volume = 0.5 × length × width × width).
[0039] Fig.13 Graph showing the mean volume of all mice from the PBS, PSiNPs, M-BSA, and M-BSA@PSiNPs groups over 23 days (n=8).
[0040] Fig.14 Graph shows the average weight of tumors harvested from all mice on day 23 (n=8).
[0041] Fig.15 Double positive F4 / 80 on day 23 + / CD80 + Populations marked in LLC tumors (n=3). Error bars are based on standard error of the mean (***P<0.001, **P<0.01 or *P<0.05 by ANOVA with Tukey's post-test).
[0042] Fig.16 For F4 / 80 on day 23 + / PD-1 - Populations marked in LLC tumors (n=3); error bars are based on standard error of the mean (***P<0.001, **P<0.01 or *P<0.05 by ANOVA with Tukey's post-test). DETAILED DESCRIPTION
[0043] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and easy to understand, the specific implementation methods of the present invention are described in detail below in conjunction with specific embodiments.
[0044] The types, specifications and sources of the reagents used in the present invention are shown in Table 1 below:
[0045] Table 1: Table of reagents used in the examples of the present invention
[0046]
[0047] Note: The reagents used in the experiments were purchased and used directly without any purification unless otherwise specified.
[0048] The instruments, models and manufacturers used in the characterization of the present invention are shown in Table 2 below:
[0049] Table 2: Instruments used in the present invention
[0050]
[0051] Example 1
[0052] A method for preparing a M-BSA@PSiNPs nanocomposite material, comprising the following steps:
[0053] (1) Preparation of M-BSA
[0054] 30.0 mg BSA was weighed and dissolved in 10 mL PBS (pH 7.2-7.4) to obtain a BSA solution. An aqueous solution of manganese chloride with a concentration of 18.9 μg / mL was added dropwise to the above BSA solution and stirred for 12 h. Subsequently, the solution was dialyzed for 24 h using a dialysis bag with MWCO=8-14 kDa and freeze-dried to obtain Mn@BSA NCs (M-BSA).
[0055] (2) Preparation of PSiNPs
[0056] First, treat the single crystal silicon with a solution of concentrated H2SO4 and H2O2 in a volume ratio of 3:1 at 80°C for 15 minutes to remove impurities on the surface of the silicon wafer. Then clean the silicon wafer with deionized water several times. When the washing solution is neutral, place it in deionized water for later use;
[0057] Next, the silicon wafer was dried with nitrogen and fixed in the electrolytic cell. The surface of the silicon wafer was cleaned with a solution of HF: deionized water = 1:1. Then, electrolyte (HF: ethanol = 3:1) was added to the electrolytic cell and 100 mA / cm 2 The silicon wafer was electrochemically etched for 15 min at the parameters of . Subsequently, the electrolytic silicon wafer was cleaned with ethanol to obtain PSiNPs. Finally, the obtained PSiNPs were ball-milled at 300 rpm for 10 h, centrifuged step by step, and the PSiNPs in the supernatant at 2000 rpm were collected and dispersed in ethanol for later use.
[0058] (3) Preparation of M-BSA@PSiNPs
[0059] The treated PSiNPs were redispersed in deionized water by centrifugation, and 500 μL of 1 mg / mL M-BSA aqueous solution was added at a ratio of 2:1. The mixture was ultrasonically treated for 30 min and allowed to stand overnight. The next day, the mixture was washed twice by centrifugation at 13,000 rpm with deionized water to obtain M-BSA@PSiNPs.
[0060] The adsorption and desorption of M-BSA were performed at a temperature of 25.0±0.1°C using a Q-sense E4 system, which consists of a shear flow unit and a piezoelectric quartz crystal sensor. Initially, a PSiNPs aqueous solution (1 mg / mL) was spin-coated onto a SiO2 chip with a pre-adsorbed PEI layer using a spin coater at a speed of 3000 r / min. The PSiNPs-coated SiO2 chip was then inserted into the chip compartment, and the PBS solution was introduced into the chip compartment. After the baseline was stabilized, a PBS solution containing 100 μg / mL M-BSA was introduced into the chip compartment. Once dynamic equilibrium was reached, the PBS solution was reintroduced to continuously rinse the SiO2 chip. Frequency changes of 15 and 35 MHz were recorded in the present invention.
[0061] Luc-LLC cell proliferation assay
[0062] Luc-LLC cells were cultured in DMEM supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin and placed at 37°C in a humidified atmosphere of 5% CO2.
[0063] In the absence or presence of density of 1×10 3 In the case of RAW 264.7 cells with a density of 8×10 3 Luc-LLC cells with a concentration range of 0-1 mg / mL were incubated with M-BSA@PSiNPs for 48 h. Subsequently, the medium containing the material was removed and fresh medium containing 0.3 mg / mL D-luciferin potassium salt was added. After incubation at 37 ° C for 10 minutes, the bioluminescence of the cell samples was measured by a multifunctional microplate reader.
[0064] In the absence or presence of density of 1×10 3 In the case of RAW 264.7 cells with a density of 8×10 3 Luc-LLC cells at 100 μg / mL were incubated with 200 (or 500 μg / mL) M-BSA@PSiNPs, 200 (or 500 μg / mL) PSiNPs, or 27 (or 67 μg / mL) equivalent M-BSA for 48 h. After 24 or 48 h, D-luciferin potassium salt was added and the bioluminescence of the cell samples was measured by a multifunctional microplate reader. The proliferation rate was calculated using the following equation:
[0065]
[0066] Preparation and characterization of M-BSA@PSiNPs
[0067] As degradable and biocompatible nanocarriers, PSiNPs are widely used in the construction of nanobiomaterial systems. Through hydrophobic interactions, PSiNPs are used to deliver multifunctional BSA nanomaterials for drug delivery, fluorescence imaging, and immunomodulation. Herein, Mn@BSA NCs (M-BSA) were delivered into macrophages using PSiNPs nanocarriers and characterized by dynamic laser scattering measurements (DLS), infrared spectroscopy (FTIR), UV-visible spectroscopy, X-ray photoelectron spectroscopy (XPS), transmission electron microscopy (TEM), and energy dispersive spectroscopy (EDS).
[0068] First, the hydrodynamic size and zeta potential of M-BSA, oxidized PSiNPs, and M-BSA@PSiNPs dispersed in deionized water were measured by DLS. Figure 1 In the experiment, the particle size of oxidized PSiNPs was 237.3±91.5nm and the PDI value was 0.1, indicating that they had good water dispersibility. In contrast, due to the loading of M-BSA (particle size of 316.7±77.7nm, PDI 0.4), the particle size of M-BSA@PSiNPs increased to 385.0±194.2nm and the PDI increased to 0.2. The zeta potential of M-BSA@PSiNPs was -1.4±3.9mV, compared with -14.3±7.5mV of oxidized PSiNPs and -4.8±4.1mV of M-BSA, which further proved that M-BSA was loaded on the surface of PSiNPs. Figure 2 In the infrared spectrum of M-BSA@PSiNPs, the absorption peaks of amide I and II of M-BSA (1641 / 1540 cm -1 ), Si-O-Si and Si-OH absorption peaks (1056 / 875cm) extending from PSiNPs -1 ), revealing that M-BSA@PSiNPs are composed of M-BSA and PSiNPs. Figure 3 The UV-visible spectrum of M-BSA showed that M-BSA had obvious absorption at 278 nm. Compared with bare PSiNPs, the appearance of the shoulder absorption peak at 278 nm verified the presence of M-BSA in M-BSA@PSiNPs.
[0069] Then, the elemental compositions of M-BSA, PSiNPs, and M-BSA@PSiNPs were analyzed using X-ray photoelectron spectroscopy. Figure 4In the spectrum, the signals of C1s (284.7 eV), N 1s (400.5 eV), O 1s (532.5 eV) and Si 2p (103.2 eV) are shown, indicating that M-BSA@PSiNPs has the composite element characteristics of M-BSA and PSiNPs. In addition, the corresponding atomic concentrations of these elements are also recorded in Table 3.
[0070] Table 3: C1s, O 1s, N 1s, S2p, Si 2p, and Mn 2p element mass concentrations of different samples
[0071]
[0072]
[0073] The Mn content in M-BSA (≈0.01%, w / w) is far below the detection limit of XPS (≈0.1%, w / w), so there is no Mn 2p elemental signal in M-BSA and M-BSA@PSiNPs. In contrast, due to the abundant content of M-BSA protein (11.9%, w / w), the elemental signal of N 1s provides a lot of information. Compared with bare PSiNPs, the N1s signal can be clearly seen in M-BSA@PSiNPs, and the concentration increases significantly from 0.0% to 9.3% (w / w). The corresponding fine spectrum shows that M-BSA has an amino peak belonging to protein at 399.8eV, and there is also a protonated (NH4+) peak at 403.2eV belonging to the protonated amino group of protein. 3+ ) peak. However, M-BSA@PSiNPs only showed a N1s peak at 399.8 eV, indicating that the M-BSA attached to PSiNPs was deprotonated. Figure 4 Negligible S2p signal of M-BSA appeared in the M-BSA@PSiNPs, which was caused by its relatively low content (1.4%, w / w, Table 3-3), but the concentration of sulfur in M-BSA@PSiNPs still increased to 0.8% (w / w), slightly higher than 0.0% of bare PSiNPs. Moreover, compared with bare PSiNPs, the concentration of silicon atoms in M-BSA@PSiNPs decreased from 39.2% to 22.4%, indicating the inhibitory effect of M-BSA encapsulation on the X-ray detection depth.
[0074] The size and morphology of PSiNPs and M-BSA@PSiNPs nanocomposites were observed by transmission electron microscopy (TEM) and energy dispersive spectroscopy (EDS), and their elemental compositions were analyzed. Figure 5In the figure, TEM images of the PSiNPs sample show that its particles are dispersed in the size range of 50-130nm. In contrast, due to the cross-linking of its outermost layer of M-BSA, these silicon particles appear to be slightly aggregated in a larger size range of 200-320nm. The TEM results at higher magnifications in the figure further show the appearance of a 10-15nm thick M-BSA layer around the PSiNPs core (marked by red arrows). At the same time, the corresponding EDS energy spectrum also shows the presence of nitrogen (0.7w / w) and sulfur (0.8w / w) element signals in M-BSA@PSiNPs, while bare PSiNPs do not (0.0% w / w).
[0075] According to the standard curve between the concentration of M-BSA and its UV absorption intensity at 278 nm ( Figure 6 ), the loading efficiency of PSiNPs nanocarriers for M-BSA was calculated to be 13.3±2.0% (w / w). The release curve of M-BSA on PSiNPs nanocarriers was also measured in normal physiological environment (pH 7.4) or intracellular / lysosomal environment (pH 5.4). Figure 7 As shown in the figure, at pH 7.4, the rapid release of M-BSA occurred within the first 3 h, and then gradually reached 50.8% saturation within 9 h. At pH 5.4, the release was faster within the first 1 h, and gradually increased to 57.9% within 9 h.
[0076] In order to further detect the in situ adsorption and desorption of M-BSA by PSiNPs in real time, a quartz crystal microbalance (QCM) was used to sensitively detect the mass change of the quartz surface by the frequency change of the oscillating crystal. Figure 8 In the experiment, similar frequency change curves were obtained at 15 and 35 Hz, revealing the adsorption and desorption of M-BSA by the PSiNPs film coated on the chip. Taking 35 Hz as an example, after rinsing with phosphate buffered saline (PBS) for 2 minutes, 100 μg / mL M-BSA solution was continuously pumped in for 9 minutes. In this process, along with the adsorption of M-BSA molecules, the frequency dropped sharply to -271.9 Hz, and then gradually reached saturation at -272.5 Hz. Subsequently, PBS solution was introduced again separately to rinse the M-BSA molecules adsorbed on the PSiNPs membrane. With the change from M-BSA to PBS solution, the frequency suddenly dropped to -291.3 Hz, and then gradually increased to -264.2 Hz after 500 minutes, indicating the slow dissociation of M-BSA molecules from the PSiNPs membrane.
[0077] The above results indicate that M-BSA can not only be loaded onto PSiNPs via hydrophobic interactions to form M-BSA@PSiNPs nanocomposites, but can also be efficiently released from PSiNPs carriers under normal or weakly acidic physiological conditions.
[0078] Example 2
[0079] An application of an M-BSA@PSiNPs nanocomposite material in preparing a drug for combating tumor growth is as follows:
[0080] Thirty-two 10-week-old female C57BL / 6J mice were randomly divided into four groups and injected subcutaneously into the axilla of the right forelimb with 1×10 7 / mL LLC cells were used to prepare an in vivo preventive tumor model. The tumor size of the mice was recorded every 2 days for 21 consecutive days. On the 21st day, three mice were randomly selected from each group and sacrificed, and single-cell suspensions isolated from the tumor were prepared for flow cytometry detection. After staining with the fixable live-dead dye eFluor 450, the single-cell suspension was incubated with anti-mouse PECy 7-CD80 antibody, FITC-PD-1 antibody, and monoclonal antibody APC-F4 / 80 to detect the co-expression of F4 / 80 / CD80 and F4 / 80 / PD-1 in macrophages.
[0081] All animal experiments were reviewed and approved by the Experimental Animal Committee of China Keygi Biotech Co., Ltd. The animal ethics review approval number is IACUC-202402103. All 10-week-old female C57BL / 6J mice were from China Spectro (Suzhou) Biotechnology Co., Ltd., and its experimental animal production license is: SCXK (Su) 2022-0006. The experimental animal license used in the experiment is: SYXK (Su) 2022-0038.
[0082] All mice in each group were housed in ventilated CP-4 mouse cages (length × width × height: 290 mm × 178 mm × 160 mm) with a 12 h light / dark cycle (07:00-19:00, light; and 19:00-07:00, dark). The temperature in the animal house was set between 20 and 26 °C, and the relative humidity was 40%-70%. The housing conditions of mice used in the experiment were in accordance with the national standards of the People's Republic of China (GB14925-2010), including bedding (GB14924.2-2001), feed (GB14924.3-2010, GB14924.2-2001), the production license was SCXK (Beijing) 2019-0003, and drinking water (GB5749-2006). All mice were allowed to have free access to food and drinking water. Finally, the surviving mice were euthanized using carbon dioxide.
[0083] Lewis lung carcinoma cells (LLC cells) that develop into epidermoid carcinoma in the lungs of C57BL / 6 mice are considered to be a typical non-small cell lung cancer cell line, highly similar to human lung adenocarcinoma. In this example, stable luciferase-expressing LLC (Luc-LLC) cells were used for macrophage-mediated in vitro non-small cell lung cancer therapy. Fig. 9 The bioluminescence intensity of the D-luciferin substrate was correlated with the number of Luc-LLC cells in the range of 0-1.2×10 5 The results showed that the proliferation of Luc-LLC cells can be accurately assessed by detecting the bioluminescence intensity of the culture medium containing D-luciferin substrate.
[0084] In the absence or presence of density of 1×10 3 In the case of RAW 264.7 cells with a density of 8×10 3 Luc-LLC cells with a concentration of 0-1 mg / mL were incubated with M-BSA@PSiNPs for 48 h. Untreated Luc-LLC cells were used as a control. At the same time, the proliferation of Luc-LLC cells was evaluated by detecting the bioluminescence of Luc-LLC cells. Fig.10As shown. The results of Luc-LLC cells co-incubated with RAW 264.7 cells alone showed negligible inhibition of their proliferation during 48 h. However, under the conditions of RAW 264.7 cells + Luc-LLC cells, M-BSA@PSiNPs in a concentration range of 0.2-1 mg / mL showed significant inhibition of Luc-LLC cell proliferation (P***<0.001, black asterisk). In contrast, in the absence of RAW 264.7 cells, the inhibitory effect of M-BSA@PSiNPs was sharply reduced (P***<0.001, black asterisk), although they became cytotoxic at higher concentrations of 0.5 or 1 mg / mL (P**<0.01 or P***<0.001, red asterisk). These results demonstrate the macrophage-mediated treatment of non-small cell lung cancer cells by M-BSA@PSiNPs. Next, the synergistic factor (α) of the combined treatment was also calculated using the equation: α = SFa × SFb / SFc (where SFa and SFb represent the proliferation levels of Luc-LLC cells treated with RAW 264.7 cells alone and M-BSA@PSiNPs alone, and SFc represents their combined treatment). α>1 means that there is a synergistic effect between the two treatments, and a larger α represents a higher degree of synergistic effect. Taking 200 μg / mL and 500 μg / mL as examples, the α values at 24 h are 1.1 (200 μg / mL) and 1.5 (500 μg / mL), or the α values at 48 h are 1.0 (200 μg / mL) and 10.7 (500 μg / mL), respectively. Therefore, the combined treatment between macrophages and M-BSA@PSiNPs has a synergistic effect on killing non-small cell lung cancer cells in vitro, especially under conditions of higher concentrations and longer incubation times.
[0085] Finally, M-BSA@PSiNPs with a concentration of 200 or 500 μg / mL were selected to further study the synergistic effect of PSiNPs and M-BSA components in killing non-small cell lung cancer cells in vitro. 3 In the case of RAW264.7 cells, the density is 8×10 3 Luc-LLC cells at 100 μg / mL were incubated with 200 μg / mL (or 500 μg / mL) M-BSA@PSiNPs, 200 μg / mL (or 500 μg / mL) PSiNPs, or 27 μg / mL (or 67 μg / mL) M-BSA for 48 h. Untreated Luc-LLC cells were used as a control in the absence of RAW 264.7. Fig.11In the experiments, M-BSA@PSiNPs showed the highest therapeutic effect even in the absence of RAW 264.7 cells (P*<0.05, P**<0.01 or P***<0.001, red asterisks). The α of the synergistic effect between PSiNPs and M-BSA components was calculated to be 1.1 (200 μg / mL+24h), 1.2 (500 μg / mL+24h), 1.2 (200 μg / mL+48h) or 1.3 (500 μg / mL+48h), respectively. 2+ The complexes or nanocomplexes of PSiNPs can aggravate the intrinsic anti-tumor effect of intracellular DNA damage, and PSiNPs nanocarriers can also promote the cellular uptake of M-BSA by non-small cell lung cancer cells, thereby enhancing its anti-cancer effect. Fig.11 In the presence of RAW 264.7 cells, M-BSA@PSiNPs showed much higher therapeutic efficacy (P*<0.05, P**<0.01 or P***<0.001, black asterisks), especially under the conditions of higher concentrations and longer incubation times. The α values were 1.3 (200μg / mL+24h), 2.0 (500μg / mL+24h), 1.3 (200μg / mL+48h) or 2.3 (500μg / mL+48h), which were correspondingly higher than those in the absence of RAW 264.7 cells. In summary, compared with M-BSA or PSiNPs alone, M-BSA@PSiNPs can more efficiently activate macrophages to secrete more proinflammatory cytokines, which can significantly enhance the macrophage-mediated therapeutic effect against non-small cell lung cancer cells in vitro.
[0086] To test the anti-NSCLC effect of M-BSA@PSiNPs in vivo, 1×10 7 LLC cells were subcutaneously implanted into the right forelimb axilla of each female C57BL / 6 mouse (10 weeks old). A total of 32 mice bearing LLC tumor models were randomly divided into 4 groups, namely PBS group, PSiNPs group, M-BSA group and M-BSA@PSiNPs group. The volume of each tumor was measured every two days from day 7 to day 23. Fig.12 shown, and in Fig.13Their average tumor volumes were also calculated. Compared with the PBS group as a control, the inhibitory efficacy on LLC tumor growth gradually increased in the order of PSiNPs, M-BSA, and M-BSA@PSiNPs groups (P***<0.001, black asterisk). Among them, M-BSA@PSiNPs showed the highest anticancer effect (P***<0.001, red asterisk). On day 23, all mice were sacrificed to measure their tumor weights, and the average tumor weights were recorded in Fig.14 The average tumor weight of the M-BSA@PSiNPs group was the smallest (P***<0.001, red asterisk), and the changes in the weights of other tumors were also similar to Fig.12 The tumor growth curves in the Figure 3 were consistent (P***<0.001, black asterisk).
[0087] Considering that M1 reprogramming of TAMs plays a crucial role in preventing proliferation and tumorigenesis of NSCLC cells, single cell suspensions isolated from LLC tumors harvested on day 23 were labeled with fixable viability dye eFluor450 (405 / 450 nm), APC-F4 / 80 antibody (638 / 660 nm) as a unique biomarker of murine macrophages, and PECy 7-CD80 antibody (561 / 785 nm) as a biomarker of M1 phenotype for flow cytometric analysis. Fig.15 In the double positive population (CD80 + / F4 / 80 + ) is shown in the M-BSA@PSiNPs group, and its percentage is much higher than that in the PBS, PSiNPs or M-BSA groups (P***<0.001, red asterisk). It is worth noting that the volume of the tumor increased ( Fig.13 ) and weight gain ( Fig.14 ) and its CD80 + / F4 / 80 + The frequency of the populations increased in exactly the same order, in the order of PBS, PSiNPs, M-BSA, and M-BSA@PSiNPs groups (P***<0.001, black asterisk). This reflects that the M1 reprogramming of TAMs induced by M-BSA@PSiNPs in non-small cell lung cancer tumors can significantly inhibit their growth, with a much higher efficiency than PBS, PSiNPs, or M-BSA.
[0088] With PD-1 +Compared with TAMs, down-regulated PD-1 expression in TAMs is positively correlated with higher levels of phagocytic activity, which can reduce tumor burden in vivo. In the present invention, single cell suspensions of LLC tumors on day 23 were also labeled with fixable live-dead dye eFluor450 (405 / 450nm), APC-F4 / 80 antibody (638 / 660nm) and FITC-PD-1 antibody (498 / 517nm) for flow cytometric analysis. Fig.16 PD-1 induced by M-BSA@PSiNPs - / F4 / 80 + The percentage of the population was higher than that of the PSiNPs or PBS group (P**<0.01 or P*<0.05, red asterisk). It is worth noting that free M-BSA can also reduce the expression level of PD-1 expression on TAMs (P*<0.05, black asterisk), similar to M-BSA@PSiNPs, with no significant difference. Therefore, the TLR4 nanoagonists M-BSA and M-BSA@PSiNPs have a certain effect on improving the phagocytosis of TAMs in non-small cell lung cancer tumors in vivo, which is beneficial to combat tumor growth.
[0089] The present invention successfully loaded M-BSA onto PSiNPs by utilizing hydrophobic interactions to prepare M-BSA@PSiNPs. The results of anti-tumor experiments in vivo and in vitro showed that the complex of PSiNPs and M-BSA exhibited a synergistic effect, making M-BSA@PSiNPs have a stronger anti-tumor effect. In addition, the combined action of macrophages and M-BSA@PSiNPs can also synergistically kill non-small cell lung cancer cells.
[0090] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. Application of M-BSA@PSiNPs nanocomposites in the preparation of anti-tumor drugs.
2. The use of the M-BSA@PSiNPs nanocomposite material according to claim 1 in the preparation of anti-tumor drugs, characterized in that: The anti-tumor drug is a drug that inhibits the growth of tumor cells.
3. The use of the M-BSA@PSiNPs nanocomposite material in the preparation of anti-tumor drugs according to claim 2, characterized in that: The tumor cells are non-small cell lung cancer cells.
4. A method for preparing the M-BSA@PSiNPs nanocomposite material as claimed in claim 1, comprising: first dissolving BSA in PBS to obtain a BSA solution, adding an aqueous solution of manganese chloride, stirring, dialyzing, and freeze-drying to obtain M-BSA; and loading M-BSA onto PSiNPs to obtain an M-BSA@PSiNPs nanocomposite material.
5. The method for preparing the M-BSA@PSiNPs nanocomposite material according to claim 4, characterized in that: The pH range of PBS is 7.2-7.4; the mass volume ratio of BSA to PBS is 29 mg-31 mg:10 mL.
6. The method for preparing the M-BSA@PSiNPs nanocomposite material according to claim 4, characterized in that: The concentration of the manganese chloride aqueous solution is 18.5 to 19.0 μg / mL.
7. The method for preparing the M-BSA@PSiNPs nanocomposite material according to claim 4, characterized in that: The method of loading M-BSA onto PSiNPs is as follows: PSiNPs are dispersed in deionized water by centrifugation, an M-BSA aqueous solution is added, the mixture is allowed to stand after ultrasonic treatment, and then centrifuged and washed with deionized water to obtain an M-BSA@PSiNPs nanocomposite material.
8. The method for preparing the M-BSA@PSiNPs nanocomposite material according to claim 7, characterized in that: The concentration of the M-BSA aqueous solution is 0.9-1.1 mg / mL; the mass ratio of PSiNPs to the M-BSA aqueous solution is 2:
1.
9. The method for preparing the M-BSA@PSiNPs nanocomposite material according to any one of claims 4 to 8, characterized in that: Here are the steps: (1) Weigh 30 mg of BSA and dissolve it in 10 mL of PBS at a pH of 7.2-7.4 to obtain a BSA solution; add an aqueous solution of manganese chloride at a concentration of 18.9 μg / mL dropwise to the BSA solution, stir, dialyze for 24 h using a dialysis bag with a MWCO of 8-14 kDa, and freeze-dry to obtain M-BSA; (2) PSiNPs were dispersed in deionized water by centrifugation, and 500 μL of 1 mg / mL M-BSA aqueous solution was added at a ratio of 2:
1. The mixture was ultrasonically treated for 30 min and allowed to stand overnight. The next day, the mixture was washed twice by centrifugation at 13,000 rpm with deionized water to obtain M-BSA@PSiNPs. 10 . The M-BSA@PSiNPs nanocomposite material prepared according to the method of claim 9 .
Citation Information
Cited By
Manganese metal albumin TLR4 agonist and preparation method thereof
CN117159692A
